P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDO...

por Quach, H., Leleu, X., Mateos, M.-V., Usmani, S. Z., Nooka, A. K., Goldrick, A., Najdi, R., Shu, N., Facon, T.
Publicado 2022

P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.

por Lasica, M., Spencer, A., Campbell, P., Wallington-Gates, C., Wong Doo, N., Janowski, W., McCaughan, G., Puliyayil, A., Yuen, F., Le, K., Reynolds, J., Quach, H.
Publicado 2022

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM...

por Quach, H., Gironella, M., Lee, C., Popat, R., Cannell, P., Kasinathan, R. S., Chopra, B., Rogers, R., Ferron-Brady, G., Shafi-Harji, S., Patel, N., Opalinska, J., Gupta, I., Augustson, B.
Publicado 2022

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM...

por Quach, H., Parmar, G., Ocio, E. M., Prince, H. M., Oriol, A., Tsukada, N., Sunami, K., Bories, P., Karanes, C., Madan, S., Semiond, D., Inchauspe, M., Macé, S., Musholt, P. B., Suzan, F., Moreau, P.
Publicado 2022

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

por Searle, E., Quach, H., Wong, S., Costa, L., Hulin, C., Janowski, W., Berdeja, J., Anguille, S., Matous, J., Touzeau, C., Michallet, A., Husnik, M., Vishwamitra, D., Niu, Z., Larsen, J., Chen, L., Goldberg, J., Popat, R., Spencer, A.
Publicado 2023

PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY M...

por Delimpasi, S., Quach, H., Cavo, M., Ho, P. J., Lee, C. H.-S., Santoro, A., Schots, R., Vlummens, P., Yoon, D. H., Yoon, S.-S., Santos, C. D., Samineni, D., Huang, J., Wehrman, K., Patil, U., Sheikh, S., Dimopoulos, M. A.
Publicado 2022

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRM...

por Nooka, A., Lonial, S., Grosicki, S., Hus, M., Song, K., Facon, T., Callander, N. S., Ribrag, V., Uttervall, K., Quach, H., Vorobyev, V., Min, C.-K., Cheng, S., Smith, L. M., Yu, J., Collingwood, T., Holkova, B., Kremer, B. E., Gupta, I. V., Richardson, P. G., Minnema, M. C.
Publicado 2022

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

por Weisel, K., Kumar, S., Moreau, P., Bahlis, N., Facon, T., Plesner, T., Orlowski, R., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C., Raje, N., Tiab1, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Krevvata, M, Carson, R, Borgsten, F., Usmani, S.
Publicado 2023

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

por Usmani, S, Alonso, A, Quach, H, Koh, Y, Guenther, A, Min, CK, Leleu, X, Abdallah, AO, Oriol, A, Bessemer, B, Garg, M, Sandhu, I, Weisel, K, Ocio San Miguel, E, Cavo, M, Zhou, X, Kaisermann, M, Mis, L, Williams, D, Yeakey, A, Ferron-Brady, G, Figueroa, D, Kremer, B, Gupta, I, Janowski, W
Publicado 2022

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

por Usmani, S. Z., Mielnik, M., Koh, Y., Alonso Alonso, A., Leleu, X., Quach, H., Min, C.-K., Janowski, W., Abdallah, A.-O., Garg, M., Sandhu, I., Ocio San Miguel, E. M., Oriol, A., Rodriquez-Otero, P., Ramasamy, K., Weisel, K., Besemer, B., Cavo, M., Zhou, X. L., Kaisermann, M. C., Bego Marques, C. M., Williams, D., Carreno, F., Kremer, B. E., Gupta, I. V., Hus, M.
Publicado 2022

P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISE...

por Chai, K. L., Wellard, C., Aoki, N., Moore, E. M., Augustson, B., Bapat, A., Blacklock, H. A., Chng, W. J., Cooke, R., Forsyth, C., Hamad, N., Harrison, S. J., Ho, P. J., Hocking, J., Kerridge, I. H., Kim, J. S., Kim, K., King, T., McCaughan, G. J., Mollee, P., Morrissey, C. O., Murphy, N., Quach, H., Tan, X. N., Tso, A., Wong, K., Spencer, A., Wood, E. M., McQuilten, Z. K.
Publicado 2022